About elias schmidt

This author has not yet filled in any details.
So far elias schmidt has created 33 blog entries.

Jeff Aronin Receives Northern Illinois University’s 2019 Innovation and Entrepreneurship Award

Jeff Aronin receives Northern Illinois University’s 2019 Innovation and Entrepreneurship Award, presented by Dr. Lisa Freeman, President of NIU, and Dr. Balaji Rajagopalan, Dean of the College of Business. Chicago, IL, May 13, 2019 – Paragon Biosciences, LLC Chairman and CEO Jeff Aronin was recently recognized by the Northern Illinois University (NIU) College of [...]

Jeff Aronin Receives Northern Illinois University’s 2019 Innovation and Entrepreneurship Award2021-12-16T12:37:51-06:00

Paragon Biosciences Names James Robinson President and Chief Operating Officer

The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments Chicago, IL, April 22, 2019 – Paragon Biosciences, LLC announced today the appointment of James (Jim) Robinson to the role of President and Chief Operating Officer, effective April 22. Reporting directly to Paragon Chairman [...]

Paragon Biosciences Names James Robinson President and Chief Operating Officer2021-12-16T12:38:31-06:00

Jeff Aronin is Named Innovator of the Year by Best in Biz

With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions. December 3, 2018 – Paragon Biosciences Chairman and CEO Jeff Aronin was named 2018’s Innovator of the Year, by Best in Biz Awards, for his lifelong commitment to developing [...]

Jeff Aronin is Named Innovator of the Year by Best in Biz2021-12-16T12:39:04-06:00

Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma

Paragon organizes new investment from Fidelity Management & Research Company and Valor Equity Partners for portfolio company Castle Creek Pharma CHICAGO, IL – October 19, 2018 – Paragon Biosciences (Paragon) today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma (Castle Creek), a Paragon portfolio company. Paragon builds innovative [...]

Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma2021-12-16T12:39:44-06:00

Crain’s Chicago Business: “Chicago-based Biotech Incubator Raises $71.8 Million”

October 19, 2019 – Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on. In an exclusive interview, Jeff shared Paragon’s announcement on the completion of a [...]

Crain’s Chicago Business: “Chicago-based Biotech Incubator Raises $71.8 Million”2021-12-16T12:40:16-06:00

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018

Paragon CEO Jeff Aronin Recognized by Insights Care Magazine as “Innovative Entrepreneur Putting Patients First” October 1, 2018 – Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has led Paragon [...]

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 20182022-05-09T15:18:56-05:00

Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies

CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline. “Skyline is working on promising therapies to treat oral precancerous lesions,” said [...]

Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies2021-12-16T12:41:25-06:00

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome

CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients [...]

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome2021-12-16T12:41:57-06:00

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast [...]

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex2021-12-16T12:42:32-06:00

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to extremely fragile skin PARSIPPANY, NJ – June 25, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the [...]

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment2021-12-16T12:43:02-06:00
Go to Top